Elevated HERV-K Expression in Soft Tissue Sarcoma Is Associated with Worsened Relapse-Free Survival

Maria Giebler††, Martin S. Staeger‡‡, Sindy Blauschmidt†, Lea I. Ohm‡, Matthias Kraus†, Peter Würl§, Helge Taubert¶ and Thomas Greither†*

† Center for Reproductive Medicine and Andrology, Martin Luther University of Halle-Wittenberg, Halle, Germany,
‡ Department of Pediatrics I, Martin Luther University of Halle-Wittenberg, Halle, Germany, ¶ Department of General, Visceral and Thoracic Surgery, Städtische Klinikum Dessau, Dessau-Roßlau, Germany, § Division Molecular Urology, Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

OPEN ACCESS

Edited by: Gikas Magiorkinis, National and Kapodistrian University of Athens, Greece
Reviewed by: George Robert Young, Francis Crick Institute, United Kingdom, César López-Camarillo, Universidad Autónoma de la Ciudad de México, Mexico, Tara Patricia Hurst, Abcam, United Kingdom
*Correspondence: Thomas Greither thomas.greither@medizin.uni-halle.de
†These authors have contributed equally to this work.

Specialty section: This article was submitted to Virology, a section of the journal Frontiers in Microbiology

Citation: Giebler M, Staeger MS, Blauschmidt S, Ohm LI, Kraus M, Würl P, Taubert H and Greither T (2018) Elevated HERV-K Expression in Soft Tissue Sarcoma Is Associated with Worsened Relapse-Free Survival. Front. Microbiol. 9:211. doi: 10.3389/fmicb.2018.00211

INTRODUCTION

Soft tissue sarcomas (STSs) are a heterogeneous group of tumors classified by the somatic tissue they resemble, with over 50 subtypes that can be distinguished (Ducimetière et al., 2011). The incidence of STS is relatively low – with estimated 4–5 cases per 100,000 per year (Still et al., 2013) – but the 5-year survival is only around 50% (Ferrari et al., 2011). Although treatment of STS usually consists of a wide resection of the tumor, followed by radio- or chemotherapy in selected cases (Casali and Blay, 2010), relapses and metastases are still an urgent clinical issue (Steinestel and Wardelmann, 2015). Due to the heterogeneity in genetics and phenotypes of the different STS entities, many of the proposed laboratory biomarkers and clinical factors still are insufficient for a satisfying prognostic evaluation of the individual patient’s outcome.
Human endogenous retroviruses (HERVs) are a class of retroviral sequences acquired during evolution by integration of viral genes in the host genome. They became non-infectious by mutation or loss of relevant genes for replication or virus release (Vargiu et al., 2016). They comprise an estimated 8% of the human genome (Lander et al., 2001), and at least 22 independent families based on their homology to known mammalian retroviruses exist (Griffiths, 2001).

Among the different families, retroviral sequences of the HERV-K family (HML-2) were the latest acquired, therefore they are the most complete and biologically active family (Bannert and Kurth, 2004; Hughes and Coffin, 2004, 2005).

### TABLE 1 | Clinical and histopathological characteristics in relation to HERV-K and HERV-F mRNA expression.

|                | HERV-K low (<0.56) | HERV-K high (>0.56) | HERV-F low (<2.02) | HERV-F high (>2.02) | Chi² test (p-value) |
|----------------|--------------------|---------------------|--------------------|---------------------|---------------------|
| Age <60 years  | 28                 | 35                  | n.s.               | 31                  | 32                  | n.s.               |
| Age >60 years  | 32                 | 25                  | 29                 | 28                  |                     |                    |
| Sex Female     | 25                 | 30                  | n.s.               | 25                  | 30                  | n.s.               |
| Sex Male       | 35                 | 30                  | 35                 | 30                  |                     |                    |
| Patients status Alive | 34             | 27                  | n.s.               | 31                  | 30                  | n.s.               |
| Patients status Deceased | 26        | 33                  | n.s.               | 29                  | 30                  |                     |
| Tumor stagea  | I 9                | 4                   | n.s.               | 7                   | 6                   | n.s.               |
| Tumor stagea  | II 21              | 34                  | 25                 | 30                  |                     |                    |
| Tumor stagea  | III 22             | 17                  | 21                 | 18                  |                     |                    |
| Tumor stagea  | IV 8               | 5                   | 7                  | 6                   |                     |                    |
| Resection Radical (R0) | 41           | 43                  | n.s.               | 39                  | 45                  | n.s.               |
| Resection Non radical (R1) | 19          | 17                  | n.s.               | 21                  | 15                  |                     |
| Tumor localization Extremities | 34      | 42                  | n.s.               | 40                  | 36                  | n.s.               |
| Tumor localization Trunk wall | 6           | 4                   | 4                  | 6                   |                     |                    |
| Tumor localization Head/neck | 2         | 2                   | 3                  | 1                   |                     |                    |
| Tumor localization Abdomen/peritoneum | 17     | 9                   | 12                 | 14                  |                     |                    |
| Tumor localization Multiple locations | 1       | 1                   | 1                  | 1                   |                     |                    |
| Histological subtypes LS | 15          | 9                   | n.s.               | 15                  | 9                   | 0.047              |
| Histological subtypes FS | 2           | 4                   | 1                  | 5                   |                     |                    |
| Histological subtypes RMS | 5          | 3                   | 5                  | 3                   |                     |                    |
| Histological subtypes LMS | 12         | 7                   | 6                  | 13                  |                     |                    |
| Histological subtypes NS | 4           | 10                  | 4                  | 10                  |                     |                    |
| Histological subtypes Syn | 2          | 8                   | 4                  | 6                   |                     |                    |
| Histological subtypes NOS | 15        | 16                  | 19                 | 12                  |                     |                    |
| Histological subtypes Other | 5         | 3                   | 6                  | 2                   |                     |                    |
| Tumor size T1  | 9                  | 10                  | n.s.               | 7                   | 12                  | n.s.               |
| Tumor size T2  | 51                 | 50                  | 53                 | 48                  |                     |                    |
| Number of relapses 0 | 43          | 31                  | (0.077)            | 37                  | 37                  | n.s.               |
| Number of relapses 1 | 7           | 13                  | 10                 | 10                  |                     |                    |
| Number of relapses >2 | 10          | 16                  | 13                 | 13                  |                     |                    |
| Metastases M0  | 45                 | 36                  | n.s.               | 46                  | 35                  | n.s.               |
| Metastases M1  | 15                 | 24                  | 14                 | 25                  |                     |                    |

One significant association (Chi² test) is marked in bold. aUnion for International Cancer Control Guidelines; LS, liposarcoma; FS, fibrosarcoma; RMS, rhabdomyosarcoma; LMS, leiomyosarcoma; NS, neuronal sarcoma; Syn, synovial sarcoma; NOS, not other specified; T1, <5 cm in diameter; T2, >5 cm in diameter.

### TABLE 2 | Sequence information on HERV-K and HERV-F amplicons.

| Amplicon length (bp) | qPCR melt analysis | Confirmed by sequencing | Amplicon sequence |
|----------------------|--------------------|-------------------------|-------------------|
| HERV-K               | 167                | Single peak              | Yes               |
|                      |                    |                         | 5'-GGCCATCGAATGCTAAAACACGAGGGNADAAAGT CCTCTTCAGCAAGGTCAAGTTGCCGTAACATTACAAACCTCAAAACGCAGGTTAAAAGAAAATAAGACCCCA ACCGCC ATGACGCTATATATATICTGCGCGCGCGCTGAACTTCACTAGATCAGGCCAAGCCAGAAGGTAAGTCAAG-3' |
| HERV-F               | 129                | Single peak              | Yes               |
|                      |                    |                         | 5'-CCTCCAGTCAACAAAGTCAGCAGTGACTGCCTCCCTTCAGCAGNCTTCCAGGTAACCCCTgcttttcTGCGGCGAAGGCTTGGCCAAACCGCTGCGTGGATGTTCCTGGCGGCCCAAGGACCTTTGCCCTTGGGATCTTTGCCGCCAGGCGCCCTTGCTCAATA3' |
HERV-K expression was detected in several tumor entities, among them chronic myeloid leukemia (Brodsky et al., 1993), renal cell carcinoma (Florl et al., 1999; Kreimer et al., 2013), breast carcinoma (Wang-Johanning et al., 2003), prostate carcinoma (Wallace et al., 2014), pancreatic cancer (Li et al., 2017), and melanoma (Serafino et al., 2009). In melanoma, HERV-K expression is suggested to be an early event in tumorogenesis, seemingly enhancing the pathological process of tumor formation (Serafino et al., 2009; Cegolon et al., 2013). Most recently, it was demonstrated that shRNA-mediated downregulation of HERV-K in pancreatic cancer cell lines suppressed growth rates and metastases as well as the expression of several proliferation-related genes (Li et al., 2017). However, it is worth mentioning that the above described associations between HERV expression and tumor tissues are correlative. It has also been demonstrated, that healthy tissues of different origins express HERV sequences, especially during early embryo development and placentation or in the innate immune response (reviewed in Meyer et al., 2017).

HERV-F is another family of HERVs originally identified by cloning of human genomic DNA sequences and homology analyses (Kjellman et al., 1999a,b). HERV-F expression was described in leukemia cell lines (Patzke et al., 2002) and in a wide range of other tumor cell lines (Yi and Kim, 2004). On the contrary, in adult somatic tissues HERV-F is only expressed in placenta (Kjellman et al., 1999a; Yi and Kim, 2004). Recently, constitutive HERV-F expression was reported in a cohort of breast cancer patients, with an increased expression of HERV-F members in comparison to normal breast tissue (Frank et al., 2008).

The knowledge on the expression and clinical impact of HERV-K and HERV-F family in STS is scarce. Schiavetti et al. (2002) reported a robust expression of HERV-K-MEL in human sarcoma specimens, which was higher than in other tumor entities and comparable to the expression in bladder and breast carcinoma, but lower than in melanoma samples. We hypothesized that a detectable HERV mRNA expression could be a common feature in STS and might be related to the patients’ clinical outcome. Therefore, the aim of this study was the quantification of HERV-K and HERV-F family mRNA expression in a cohort of 120 STS samples and the correlation to clinicopathological and prognostic data of the patients. Furthermore, as a secondary end point we analyzed the correlation of the mRNA expression of HERV-K and HERV-F with the RNA expression of known apoptosis-related (B-cell cll/lymphoma 2 (BCL2)) or hypoxia-related (miR-210, miR-199a, Hypoxia inducible factor 1a) genes as well as known epigenetically regulated genes (miR-203, H2A.Bbd).

MATERIALS AND METHODS

Patients

One hundred and twenty STS patients agreed to participate in this study. An overview of the patient cohort is given in Table 1. Patients underwent tumor surgical resection between 1998 and 2001 at the Department of Surgery, University of Leipzig (Leipzig, Germany) without prior adjuvant treatment. Thirty-nine patients exhibited metastases (32.5%). Fresh tumor tissue was snap-frozen immediately after excision and stored at −80°C until RNA isolation. The study was approved by the local ethics committee of the Medical Faculty of the Martin Luther University of Halle-Wittenberg and the Medical Faculty of the University of Leipzig. According to the Helsinki Declaration, all patients gave written informed consent. Patient cohort composition as well as tissue cryopreservation was as described previously (Kappler et al., 2001; Würl et al., 2002).

RNA Isolation

Tissue specimens were partly processed on a cryotome in 5 µm tissue slices, and RNA was isolated from 20 tissue slices. The slices were incubated in Trizol (Thermo Fisher Scientific, Waltham, MA, United States) for 5 min at room temperature and subsequently mixed with chloroform (AppliChem, Darmstadt, Germany). After centrifugation, aqueous phase was collected and treated with DNase (Qiagen, Hilden, Germany). Total
RNA was precipitated with isopropanol (AppliChem, Darmstadt, Germany) for 12 h at 4°C, washed with different ice-cooled ethanol solutions (96 and 70%) and finally dissolved in RNase-free water (Qiagen, Hilden, Germany). RNA concentrations were assessed spectrometrically.

**cDNA Synthesis and qPCR**

cDNA synthesis was carried out with RevertAid First strand synthesis kit (Thermo Fisher Scientific, Waltham, MA, United States) according to manufacturer’s protocol. One µg total RNA was applied for cDNA synthesis per tissue specimen. The complete elimination of genomic DNA was controlled by mock-RT PCR reactions (see Supplementary Figures S1, S2). cDNA was quantified with Maxima SyBR Green Kit (Thermo Fisher Scientific, Waltham, MA, United States) in a quantitative real-time-PCR reaction. The applied primer sequences for the PCR reaction were: HERV-K forward: 5′-GGCAT CAG AGT CTA AAC CAC G-3′; HERV-K reverse: 5′-CTG ACT TTT GGG TGG CCG-3′; HERV-F forward: 5′-CCT CCA GTC ACA ACA ACT C-3′; HERV-F reverse: 5′-TAT TGA AGA AGG CGG CTG G-3′ (Seifarth et al., 2005); H2A.Bbd forward: 5′-TCG TTT TCA GTA GCC AGG T-3′; H2A.Bbd reverse: 5′-CAG AAT TAA TGA AGG CCC AAG-3′; HPRT forward: 5′-TGG CTG ACC TGG TGC ATT AC-3′; HPRT reverse: 5′-CTT GCG ACC TTT ACC ATC TT-3′. Samples were run on a MyIQ cycler (BioRad, Hercules, CA, United States) and HERV-K or HERV-F expression calculated according to the 2−ΔCT method (Schmittgen and Livak, 2008) with HPRT as reference gene. Linearity of the qPCR reaction for both HERV-K and HERV-F was analyzed by dilution series of the gel-extracted amplicon (see Supplementary Figure S3). All amplicons were analyzed by qPCR melt analyses on the occurrence of a single, distinct peak (see Supplementary Figures S4, S5). Representative PCR products were purified by agarose gel electrophoresis and subsequently sequenced (see Table 2). Analysis of the sequenced PCR products with RepeatMasker demonstrated that the used primers amplified sequences from HERV-K and HERV-Fb (HERVFH21). Expression analyses for BCL2 mRNA, miR-203 and miR-210 (Greither et al., 2012), HIF-1α mRNA (Kessler et al., 2010) and miR-199a (Kefler et al., 2016) were carried out as previously described.

**Statistical Analyses**

Statistical analyses were performed with SPSS 20.0 (IBM Statistics, Ehingen, Germany). HERV expression data were analyzed with bivariate correlation analyses (Spearman rank correlation) and Chi² tests. Survival analyses were performed with Kaplan–Meier analyses and multivariate Cox’s Regressions analyses adjusted for resection status, localization of the tumor, tumor entity, and tumor stage (inclusion).

**RESULTS**

**HERV-K and -F Expression in Soft Tissue Sarcoma Samples**

HERV-K mRNA expression was detected in 120 patients samples with a mean expression of 4.1 (range: 0.05–95.6; 2−ΔCT value). HERV-F mRNA expression was also detected in 120 patients sarcoma specimen with a mean expression of 0.361 (2−ΔCT value). HERV-F expression in normal skeletal muscle tissue. HERV-K mRNA expression was determined at 0.093 (2−ΔCT value). Samples were run on a MyIQ cycler (BioRad, Hercules, CA, United States) and HERV-K or HERV-F expression calculated according to the 2−ΔCT method (Schmittgen and Livak, 2008) with HPRT as reference gene. Linearity of the qPCR reaction for both HERV-K and HERV-F was analyzed by dilution series of the gel-extracted amplicon (see Supplementary Figure S3). All amplicons were analyzed by qPCR melt analyses on the occurrence of a single, distinct peak (see Supplementary Figures S4, S5). Representative PCR products were purified by agarose gel electrophoresis and subsequently sequenced (see Table 2). Analysis of the sequenced PCR products with RepeatMasker demonstrated that the used primers amplified sequences from HERV-K and HERV-Fb (HERVFH21). Expression analyses for BCL2 mRNA, miR-203 and miR-210 (Greither et al., 2012), HIF-1α mRNA (Kessler et al., 2010) and miR-199a (Kefler et al., 2016) were carried out as previously described.

**TABLE 3 | Bivariate correlations (Spearman’s rank test; r_s) of HERV-K or HERV-F mRNA expression with several clinicopathological and molecular parameters.**

| HERV-K mRNA | r_s | p  | n  |
|-------------|-----|----|----|
| Tumor diameter | −0.309 | 0.001 | 120 |
| BCL2 mRNA expression | −0.408 | 0.0002 | 77 |
| miR-210 expression | 0.399 | 0.001 | 71 |
| miR-203 expression | 0.199 | 0.098 | 70 |
| HIF-1a mRNA expression | 0.444 | 3.0 × 10−6 | 102 |
| miR-199a expression | 0.361 | 0.0004 | 94 |
| H2A.Bbd expression | 0.456 | 0.0009 | 68 |
| HERV-F mRNA expression | 0.499 | 6.4 × 10−9 | 120 |

| HERV-F mRNA | r_s | p  | n  |
|-------------|-----|----|----|
| Tumor diameter | −0.467 | 7.4 × 10−8 | 120 |
| BCL2 mRNA expression | −0.207 | 0.071 | 77 |
| miR-210 expression | 0.366 | 0.002 | 71 |
| miR-203 expression | 0.333 | 0.005 | 70 |
| HIF-1a mRNA expression | 0.359 | 0.0002 | 102 |
| miR-199a expression | 0.116 | 0.264 | 94 |
| H2A.Bbd expression | 0.302 | 0.012 | 68 |
| HERV-K mRNA expression | 0.499 | 6.4 × 10−9 | 120 |

Significant p-values are marked in bold.
according to the median as cut-off value (HERV-K: 0.56; HERV-F: 2.02). In Chi² tests, low or elevated HERV-K expressions exhibited no correlation to demographic (age, sex) or clinical parameters (tumor entity or localization, resection type, tumor size, number of relapses, and patients status). In contrast, a significant correlation of HERV-F expression with the histological subtype of the STS was observed ($p = 0.047$).

### Association of HERV Expression with Clinicopathological Parameters

In bivariate regression analyses, the association between HERV-K or HERV-F expression and several clinicopathological parameters were tested (see Table 3). Interestingly, HERV-F and HERV-K expression was significantly associated ($r_S = 0.499$; $p = 6.4 \times 10^{-9}$). Both HERV-F and HERV-K expression exhibited a significant inverse association with the actual tumor diameter at surgery ($r_S = -0.309$; $p = 0.001$ and $r_S = -0.467$; $p = 7.4 \times 10^{-8}$, respectively). Moreover, HERV-K mRNA expression was significantly inversely associated with BCL2 mRNA expression ($r_S = -0.408$; $p = 0.0002$) and miR-199a ($r_S = 0.361$; $p = 0.0004$) expression, while solely HERV-F expression was significantly associated with miR-203 expression ($r_S = 0.333$; $p = 0.005$). Intriguingly, both HERV-K and HERV-F expression were significantly associated with levels of hypoxia-related genes like HIF-1α mRNA expression ($r_S = 0.444$; $p = 3.0 \times 10^{-6}$ and 0.359; $p = 0.0002$; respectively) or miR-210 expression ($r_S = 0.399$; $p = 0.001$ and $r_S = 0.366$; $p = 0.002$; respectively). Additionally, both HERV-K and HERV-F expression were significantly associated to H2A.Bbd mRNA expression ($r_S = 0.456$; $p = 0.0009$ and $r_S = 0.302$; $p = 0.012$, respectively).

### HERV-K or F Expression and Patients’ Survival

In Kaplan–Meier analyses, while HERV-F mRNA expression showed no significant correlation to patients’ disease-specific survival, a lower HERV-K mRNA expression was in trend associated with a worsened survival ($p = 0.08$; log rank test). Further, in a multivariate Cox’s regression analysis adjusted to the confounders resection type, tumor localization, tumor histotype and staging, there was no significant correlation between HERV-K or HERV-F mRNA expression and patient survival (see Supplementary Figure S6). Interestingly, when analyzing the relapse-free survival in Kaplan–Meier analyses, patients with a lower HERV-K mRNA expression exhibited a significantly longer relapse-free survival ($p = 0.014$; log-rank test, see Figure 2A). A comparable effect was observed in patients with lower HERV-F mRNA expression; however, there it was not significant ($p = 0.22$, see Figure 2B). Additionally, when analyzing the effect of the HERV-K mRNA expression on the relapse-free survival in a multivariate Cox’s regression analysis, an elevated HERV-K mRNA expression was in trend associated with a 1.78-fold increased risk for a relapse ($p = 0.08$). Furthermore, when comparing only patients exhibiting low HERV-F and HERV-K ($n = 43$) with patients exhibiting both elevated HERV-F and HERV-K expression ($n = 43$) in a multivariate Cox’s regression analysis, an elevated expression of HERVs was in trend significantly associated with a 2.08-fold increased relative risk for a relapse ($p = 0.066$).

### DISCUSSION

In this study, we demonstrated that a robust mRNA expression of HERV-K and HERV-F in a cohort of 120 STS samples is detectable, and that the expression of HERV-K and HERV-F is correlated with clinicopathological features and hypoxia-related gene expression. Furthermore, an elevated HERV-K mRNA expression was significantly associated with a shorter relapse-free survival.

There are only few data on the expression of HERVs in STS. Schiavetti and colleagues studied the expression of HERV-K-MEL in sarcoma in comparison to the expression in a patient’s sample of melanoma cells. This transcript was detectable in 9/23 (39.1%) of sarcoma samples (Schiavetti et al., 2002). There is no data on the expression of HERV-F in sarcoma, however, one report shows a wide expression of HERV-F in tumor cell lines originating from mamma carcinoma, ovarian carcinoma, pancreatic adenocarcinoma, prostate carcinoma, glioblastoma, and others (Yi and Kim, 2004). Interestingly, HERV-F expression...
was not detected in any somatic tissue tested, with the exception of placenta (Yi and Kim, 2004). These reports are consistent with the assumption that HERV sequences are normally methylated and therefore transcriptionally inactive, but are hypomethylated and activated during carcinogenesis (Kreimer et al., 2013; Hurst and Magiorkinis, 2017). Concordantly, the treatment with 5′-azacytidine, a known DNA methyltransferase inhibitor, activates HERV sequences in diverse tumor cell lines (Strissel et al., 2012; Laska et al., 2013; Chiappinelli et al., 2015). Therefore, we propose that re-induction of HERVs may also occur during the multi-step process of sarcomagenesis.

Intriguingly, we identified a significant association of the HERV-K and -F expression with those of the hypoxia-related genes HIF-1α and miR-210. HIF-1α is a key regulator of the hypoxic response, and miR-210 is the most prominent microRNA upregulated by hypoxia (Kulshreshtha et al., 2007). There is little knowledge about interactions between HERV expression and hypoxic response. It has been described, that the hypoxia-mimetic CoCl₂ increases the expression of ERV3 in Hodgkin’s lymphoma cell lines, and that this increase in ERV3 expression might be associated with a pro-apoptotic reaction (Kewitz and Staeg, 2013). Other groups demonstrated upregulation of the HERV-W expression in neuroblastoma cell lines due to hypoxic conditions (Hu et al., 2016) or upregulation of the HERV-E expression in renal cell carcinomas due to inactivation of the von Hippel-Lindau factor and subsequent stabilization of the oxygen sensor protein HIF-1α (Cherkasova et al., 2011). In our ex vivo samples, we detected an inverse association between HERV-K and BCL2 mRNA expression, implying that HERV-K overexpression could be associated with apoptosis-induction. However, other reports performed on in vitro cell cultures demonstrate that the HERV-K family exerts an anti-apoptotic role (Broecker et al., 2016). Further research on this contradiction is warranted.

Furthermore, HERV-K and HERV-F expression were both significantly correlated to the mRNA expression of H2A.Bbd, a histone A2 variant encoded on the X chromosome, which is found to be associated with the nucleosomes of transcriptionally active genomic regions (Chadwick and Willard, 2001). H2A.Bbd was further shown to induce a more relaxed structure of the DNA by destabilizing the nucleosome (Bao et al., 2004; Doyen et al., 2006), which resembles the genomic reorganization induced by histone acetylation in a modification-independent manner (Eirín-López et al., 2008). A recent report showed H2A.Bbd to localize temporarily on replication-active DNA regions. By this mechanism, H2A.Bbd is holding the DNA in a more decondensed state, thereby increasing S-phase progression (Sansoni et al., 2014). Thus, it can be speculated that an H2A.Bbd overexpression in patient samples may be associated with a more transcriptionally active genome resulting in an increased chance of reactivation and expression HERV species.

In our patient cohort, we detected a significant association between a lower HERV-K expression and a longer relapse-free survival. This is concordant with previous reports describing a better overall prognosis for patients with a lower HERV-K expression in breast cancer (Golan et al., 2008; Zhao et al., 2011) or hepatocellular carcinoma (Ma et al., 2016). Additionally, hypomethylation and subsequent HERV induction was also demonstrated in ovarian carcinoma, and specifically the extent HERV-K hypomethylation was associated with a poor prognosis and therapy resistance in ovarian carcinoma patients (Menendez et al., 2004; Irmaneerat et al., 2011).

CONCLUSION

To the best of our knowledge we present the first report suggesting an involvement of the HERV-K expression in the clinical course of STS. From our ex vivo data, we also suggest that HERV-K and -F expression may be regulated directly or indirectly by tumor hypoxia. Furthermore, HERV-K was associated to apoptosis in our samples, therefore may be an interesting therapeutic target.

AUTHOR CONTRIBUTIONS

MG performed the data analysis and revised the manuscript; SB, LO, and MK carried out the clinical sample processing and the qPCR measurements; PW recruited the patients and collected the tissue specimen; TG, HT, and MS conceived the study design, prepared and revised the manuscript. All authors read and approved the final version of the manuscript.

ACKNOWLEDGMENTS

The authors want to thank Ines Volkmer for excellent technical assistance. They also acknowledge the financial support of the Open Access Publication Fund of the Martin Luther University of Halle-Wittenberg.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2018.00211/full#supplementary-material
an indicator of malignant transformation. *Mol. Cell 7:25. doi: 10.1186/s1300-016-0081-9*

Casali, P. G., and Blay, J.-Y. (2010). Soft tissue sarcomas: ESMo clinical practice guidelines for diagnosis, treatment and follow-up. *Ann. Oncol. 21(Suppl. 5), v198–203. doi: 10.1093/annonc/mdq209*

Cegolón, L., Salata, C., Weidner, E., Vincze, P., Pali, G., and Mastrangelo, G. (2013). Human endogenous retrovirus and cancer prevention: evidence and prospects. *BMC Cancer 13:4. doi: 10.1186/1471-2407-13-4*

Chadwick, B. P., and Willard, H. F. (2001). A novel chromatin protein, distantly related to histone H2A, is largely excluded from the inactive X chromosome. *J. Cell Biol. 152, 375–384. doi: 10.1083/jcb.152.2.375*

Cherkasova, E., Malinízková, E., Rao, S., Takahashi, Y., Senchenko, V. N., Chadwick, B. P., and Willard, H. F. (2001). A novel chromatin protein, distantly related to histone H2A, is largely excluded from the inactive X chromosome. *J. Cell Biol. 152, 375–384. doi: 10.1083/jcb.152.2.375*

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., et al. (2015). Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. *Cell 162, 974–986. doi: 10.1016/j.cell.2015.07.011*

Doyen, C.-M., Montel, F., Gautier, T., Claudet, C., Menoni, H., Delacourte, A., Desrichard, A., Li, H., Henke, C., Akman, B., et al. (2015). Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. *Cell 162, 974–986. doi: 10.1016/j.cell.2015.07.011*

Greither, T., Würl, P., Grochola, L., Bond, G., Bache, M., Kappler, M., et al. (2016). miR-199a-5p regulates HIF-1α and OSCN2 and its expression is correlated to soft-tissue sarcoma patients’ outcome. *Oncol. Lett. 12, 5281–5288. doi: 10.3892/ol.2016.5320*

Kjellman, C., Björkman, H. O., Salford, L. G., and Widgren, B. (1999a). HERV-F (XA34) is a full-length human endogenous retrovirus expressed in placental and fetal tissues. *Gene 239, 99–107. doi: 10.1016/s0378-1119(99)00097-9*

Kjellman, C., Björkman, H. O., and Widgren, B. (1999b). HERV-F, a new group of human endogenous retrovirus sequences. *J. Gen. Virol. 80(Pt 9), 2583–2592. doi: 10.1099/ijc.2013.01956-0*

Kjellman, C., Björkman, H. O., and Widgren, B. (1999b). HERV-F, a new group of human endogenous retrovirus sequences. *J. Gen. Virol. 80(Pt 9), 2583–2592. doi: 10.1099/ijc.2013.01956-0*

Kreimer, A., Wetterwald, T., Koch, A., Niegisch, G., and Groer, W. (2013). HERV-K and LINE-1 DNA methylation and reexpression in Urothelial Carcinoma. *Front. Oncol. 3:235. doi: 10.3389/fonc.2013.00255*

Kurihara, Y., Yamada, Y., and Yamada, K. (2007). HERV-K and LINE-1 DNA methylation and reexpression in Urothelial Carcinoma. *Front. Oncol. 3:235. doi: 10.3389/fonc.2013.00255*

Kulshreshtha, R., Ferrara, C., Kestler, H. A., Tanke, H. J., and Bignami, A. (2001). Human endogenous retrovirus (HERV) reverse transcriptase activity in human primary tumors and normal tissues. *Cell 101, 79–89. doi: 10.1016/s0092-8674(01)00013-9*

Kyd, D., Radavanyi, J., Yin, B., Li, J., Chivukula, R., Li, S., et al. (2017). Down-regulation of human endogenous retrovirus type K (HERV-K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth. *Clin. Cancer Res. 23, 5892–5911. doi: 10.1158/1078-0432.CCR-17-0001*

Li, M., Radvanyi, L., Yin, B., Li, J., Chivukula, R., Lin, K., et al. (2017). Down-regulation of human endogenous retrovirus type K (HERV-K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth. *Clin. Cancer Res. 23, 5892–5911. doi: 10.1158/1078-0432.CCR-17-0001*

Ma, W., Zheng, Z., Liu, H., Chen, X., Ding, L., Liu, Z., et al. (2016). Human endogenous retrovirus-K (HERV-K) expression is correlated with prognosis and progression of hematopoietic cell malignancy. *BioMed Res. Int. 2016:8201642. doi: 10.1155/2016/8201642*

Menendez, L., Benigno, B. A., and McDonald, J. F. (2004). L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. *Mol. Cancer 3:12. doi: 10.1186/1476-4598-3-12*

Meyer, T. J., Rosenkrantz, J. L., Carbone, L., and Chavez, S. L. (2017). Endogenous retroviruses: with us and against us. *Front. Oncol. 7, 264. doi: 10.3389/fonc.2017.00264*

Patzek, S., Lindsenkog, M., Munthe, E., and Aasheim, H. C. (2002). Characterization of a novel human endogenous retrovirus, HERV-H/F, expressed in human leukemia cell lines. *Virology 303, 164–173. doi: 10.1006/viro.2002.1615*

Sansoni, V., Casas-Delucchi, C. S., Rajan, M., Schmidt, A., Bönisch, C., Thomae, A. W., et al. (2014). The histone variant H2A.Bbd is enriched at sites of DNA demethylation. *Cell 157, 983–996. doi: 10.1016/j.cell.2014.05.004*

Seifarth, W., Frank, O., Zeilfelder, U., Pietsch, T., Bertschinger, B., and Aasheim, H. C. (2002). Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. *J. Virol. 76, 341–352. doi: 10.1128/JVI.76.1.341-352.2002*

Serafini, A., Balestrieri, E., Pierimarchi, P., Matteucci, C., Moroni, G., Orichio, E., et al. (2009). The activation of human endogenous retrovirus K (HERV-K)
is implicated in melanoma cell malignant transformation. Exp. Cell Res. 315, 849–862. doi: 10.1016/j.yexcr.2008.12.023

Steinestel, K., and Wardelmann, E. (2015). Metastasierung und Progressionsmechanismen von Weichteiltumoren. Pathologe 36(Suppl. 2), 167–170. doi: 10.1007/s00292-015-0072-5

Stiller, C. A., Trama, A., Serraino, D., Rossi, S., Navarro, C., Chirlaque, M. D., et al. (2013). Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur. J. Cancer 49, 684–695. doi: 10.1016/j.ejca.2012.09.011

Strissel, P. L., Ruebner, M., Thiel, F., Wachtler, D., Ekici, A. B., Wolf, F., et al. (2012). Reactivation of codogenic endogenous retroviral (ERV) envelope genes in human endometrial carcinoma and prestages: emergence of new molecular targets. Oncotarget 3, 1204–1219. doi: 10.18632/oncotarget.679

Vargiu, L., Rodriguez-Tomé, P., Sperber, G. O., Cadeddu, M., Grandi, N., Blikstad, V., et al. (2016). Classification and characterization of human endogenous retroviruses; mosaic forms are common. Retrovirology 13:7. doi: 10.1186/s12977-015-0232-y

Wallace, T. A., Downey, R. F., Seufert, C. J., Schetter, A., Dorsey, T. H., Johnson, C. A., et al. (2014). Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers. Carcinogenesis 35, 2074–2083. doi: 10.1093/carcin/bgu114

Wang-Johanning, F., Frost, A. R., Jian, B., Epp, L., Lu, D. W., and Johanning, G. L. (2003). Quantitation of HERV-K env gene expression and splicing in human breast cancer. Oncogene 22, 1528–1535. doi: 10.1038/sj.onc.1206241

Würl, P., Kappler, M., Meye, A., Bartel, F., Kohler, T., Lautenschläger, C., et al. (2002). Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma. Lancet 359, 943–945. doi: 10.1016/S0140-6736(02)07990-4

Yi, J.-M., and Kim, H.-S. (2004). Expression analysis of endogenous retroviral elements belonging to the HERV-F family from human tissues and cancer cells. Cancer Lett. 211, 89–96. doi: 10.1016/j.canlet.2004.01.026

Zhao, J., Rycjaj, K., Geng, S., Li, M., Plummer, J. B., Yin, B., et al. (2011). Expression of human endogenous retrovirus type K envelope protein is a novel candidate prognostic marker for human breast cancer. Genes Cancer 2, 914–922. doi: 10.1177/1947601911431841

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Giebler, Staege, Blauschmidt, Ohm, Kraus, Würl, Taubert and Greither. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.